Alaska Tuberculosis Program Manual - Epidemiology - State of Alaska
Alaska Tuberculosis Program Manual - Epidemiology - State of Alaska Alaska Tuberculosis Program Manual - Epidemiology - State of Alaska
Immunocompromised Contacts and Children under 5 Use Figure 4 to select evaluation, treatment, and follow-up activities for contacts who are immunocompromised and/or under 5 years old. FIGURE 4: Evaluation, Treatment, and Follow-up of Immunocompromised Contacts and Children under 5 years old 53 A L A S K A T U B E R C U L O S I S P R O G R A M M A N U A L Contact Investigation 11.33 Revised November 2012
Definition of abbreviations: HIV = human immunodeficiency virus; IGRA = interferon gamma release assay; LTBI = latent tuberculosis infection; TST = tuberculin skin test. Note: An IGRA may be used in place of a TST. Source: CDC. Guidelines for the investigation of contacts of persons with infectious tuberculosis; recommendations from the National Tuberculosis Controllers Association and CDC, and guidelines for using the QuantiFERON ® -TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR 2005;54(No. RR-15):15. Evaluate contacts who are immunocompromised or under 5 years of age with medical history, physical examination, chest radiograph, and tuberculin skin test (TST) or interferon gamma release assay (IGRA). Based on the results of these evaluations, take the actions in Figure 4. Timely initiation of treatment is especially important for these contacts. Refer to Table 3: Time Frames for Contact Evaluation and Treatment in the “Time Frames for Contact Investigation” topic. A L A S K A T U B E R C U L O S I S P R O G R A M M A N U A L Contact Investigation 11.34 Revised November 2012
- Page 247 and 248: Completion of Therapy The case mana
- Page 249 and 250: Case Closures Other than Completion
- Page 251 and 252: Conduct a case management meeting o
- Page 253 and 254: Biweekly (BIW) doses of TB medicati
- Page 255 and 256: Use DOT with other measures such as
- Page 257 and 258: It is important not to send a mixed
- Page 259 and 260: Medical Orders Progressive Interven
- Page 261 and 262: CDC. Module 9: “Patient Adherence
- Page 263 and 264: 36 New Jersey Medical School Nation
- Page 265 and 266: 75 CDC. Module 9: patient adherence
- Page 267 and 268: Introduction Purpose A contact inve
- Page 269 and 270: For roles and responsibilities, ref
- Page 271 and 272: Decision to Initiate a Contact Inve
- Page 273 and 274: chest radiographic findings that ar
- Page 275 and 276: In general, a contact investigation
- Page 277 and 278: Time Frames for Contact Investigati
- Page 279 and 280: Circumstances unique to Alaska may
- Page 281 and 282: Circumstances unique to Alaska may
- Page 283 and 284: Activity Purpose Maximum Time Inter
- Page 285 and 286: Infectious Period Determine the inf
- Page 287 and 288: In general, for the purposes of con
- Page 289 and 290: General Guidelines for Interviewing
- Page 291 and 292: Healthcare workers should remember
- Page 293 and 294: Index Patient with Positive Acid-Fa
- Page 295 and 296: Index Patient with Negative Acid-Fa
- Page 297: Contact Evaluation, Treatment, and
- Page 301 and 302: Note: An IGRA may be used in place
- Page 303 and 304: When to Expand a Contact Investigat
- Page 305 and 306: Figure 7: EVALUATION, TREATMENT, AN
- Page 307 and 308: CDC’s “Framework of Program Eva
- Page 309 and 310: Definitions of abbreviations: AIDS
- Page 311 and 312: elease assay; LTBI = latent tubercu
- Page 313 and 314: officials to distinguish between di
- Page 315 and 316: References 1 ATS, CDC, IDSA. Contro
- Page 317 and 318: 44 CDC, NTCA. Guidelines for the in
- Page 319 and 320: Introduction Purpose Use this secti
- Page 321 and 322: Available Laboratory Tests Table 2:
- Page 323 and 324: Table 3: PCR Testing Algorithm and
- Page 325 and 326: Table 4: SPECIMEN COLLECTION METHOD
- Page 327 and 328: 5. If possible, send the specimen o
- Page 329 and 330: Specimen Shipment There are three m
- Page 331 and 332: Resources and References Resources
- Page 333 and 334: Patient Education CONTENTS Introduc
- Page 335 and 336: treatment, common side-effects of m
- Page 337 and 338: Education Topics During the initial
- Page 339 and 340: 10. Explain the signs and symptoms
- Page 341 and 342: Patient Education Materials Get th
- Page 343 and 344: References 1 CDC. Module 4: treatme
- Page 345 and 346: Introduction Purpose Use this secti
- Page 347 and 348: National Guidelines The following g
Definition <strong>of</strong> abbreviations: HIV = human immunodeficiency virus; IGRA = interferon gamma release assay; LTBI = latent<br />
tuberculosis infection; TST = tuberculin skin test.<br />
Note: An IGRA may be used in place <strong>of</strong> a TST.<br />
Source: CDC. Guidelines for the investigation <strong>of</strong> contacts <strong>of</strong> persons with infectious tuberculosis; recommendations from<br />
the National <strong>Tuberculosis</strong> Controllers Association and CDC, and guidelines for using the QuantiFERON ® -TB Gold test<br />
for detecting Mycobacterium tuberculosis infection, United <strong>State</strong>s. MMWR 2005;54(No. RR-15):15.<br />
Evaluate contacts who are immunocompromised or under 5 years <strong>of</strong> age with medical<br />
history, physical examination, chest radiograph, and tuberculin skin test (TST) or<br />
interferon gamma release assay (IGRA). Based on the results <strong>of</strong> these evaluations, take<br />
the actions in Figure 4.<br />
Timely initiation <strong>of</strong> treatment is especially important for these contacts.<br />
Refer to Table 3: Time Frames for Contact Evaluation and Treatment in<br />
the “Time Frames for Contact Investigation” topic.<br />
A L A S K A T U B E R C U L O S I S P R O G R A M M A N U A L Contact Investigation 11.34<br />
Revised November 2012
Change language